Transforming
ALK
+ aNSCLC into a
chronic condition: What the CROWN
7‑year data mean for patients
Tuesday, 16 June 2026 Wednesday, 17 June 2026 SPEAKERS
Prof. Tony Mok (Hong Kong) Prof. Tony Mok
(Hong Kong) Prof. Tony Mok is the Chairman of Clinical Oncology at the Chinese University of Hong Kong, specialising in biomarker and molecular targeted therapy in lung cancer.
His expertise in precision medicine for lung cancer is highlighted by his leadership in pivotal clinical trials that have influenced the current management of advanced lung cancer globally.
Prof. Mok is widely published in international peer-reviewed journals and is Past President and Past Treasurer of the International Association for the Study of Lung Cancer.
His expertise in precision medicine for lung cancer is highlighted by his leadership in pivotal clinical trials that have influenced the current management of advanced lung cancer globally.
Prof. Mok is widely published in international peer-reviewed journals and is Past President and Past Treasurer of the International Association for the Study of Lung Cancer.
Prof. Geoffrey Liu (Canada) Prof. Geoffrey Liu
(Canada)Prof. Geoffrey Liu is the M. Qasim Chair in Lung Cancer Translational Research at Princess Margaret Cancer Centre in Toronto. He is Professor of Medicine, Pharmacology and Toxicology, Medical Biophysics, and Epidemiology, at the Institute of Medical Science at the Dalla Lana School of Public Health and the University of Toronto in Canada.
Prof. Liu’s clinical work focuses on lung cancer and thymic neoplasms, while his research focuses on cancer of the upper aerodigestive and thoracic system.
He has authored over 600 peer-reviewed publications, held over 50 peer-reviewed grants, and participated in over 60 clinical trials.
Prof. Liu is also deeply engaged in advocacy. He is the current co-chair of the Medical Advisory Committee for Lung Cancer Canada and sits on the steering committee of the Canadian Lung Cancer Action Plan through the Canadian Cancer Society.
Prof. Liu’s clinical work focuses on lung cancer and thymic neoplasms, while his research focuses on cancer of the upper aerodigestive and thoracic system.
He has authored over 600 peer-reviewed publications, held over 50 peer-reviewed grants, and participated in over 60 clinical trials.
Prof. Liu is also deeply engaged in advocacy. He is the current co-chair of the Medical Advisory Committee for Lung Cancer Canada and sits on the steering committee of the Canadian Lung Cancer Action Plan through the Canadian Cancer Society.
Dr Justin Gainor (USA) Dr Justin Gainor
(USA)Dr Gainor is a medical oncologist specialising in thoracic malignancies and early-phase clinical trials. He is currently Division Chief for Solid Tumor Medical Oncology at the Massachusetts General Brigham Cancer Institute. His research focuses on the clinical development of novel targeted therapies and immunotherapies. In parallel, his translational research efforts centre around developing predictive biomarkers and elucidating mechanisms of resistance to therapy.
Dr Gainor completed his undergraduate training at Johns Hopkins University and received his medical degree from Harvard Medical School. He subsequently completed his training in internal medicine at the Massachusetts General Hospital and training in medical oncology in the combined Massachusetts General Brigham/Dana-Farber Cancer Institute fellowship programme. In addition to his appointment at Massachusetts General Hospital, Dr Gainor is currently an associate professor of medicine at Harvard Medical School.
Dr Gainor has led several Phase 1–3 clinical trials and is involved in multi-institutional collaborative efforts focused on biomarker discovery. He is a member of the European Society for Medical Oncology Translational Research and Precision Medicine Working Group.
Dr Gainor completed his undergraduate training at Johns Hopkins University and received his medical degree from Harvard Medical School. He subsequently completed his training in internal medicine at the Massachusetts General Hospital and training in medical oncology in the combined Massachusetts General Brigham/Dana-Farber Cancer Institute fellowship programme. In addition to his appointment at Massachusetts General Hospital, Dr Gainor is currently an associate professor of medicine at Harvard Medical School.
Dr Gainor has led several Phase 1–3 clinical trials and is involved in multi-institutional collaborative efforts focused on biomarker discovery. He is a member of the European Society for Medical Oncology Translational Research and Precision Medicine Working Group.
Prof. Sanjay Popat (UK) Prof. Sanjay Popat
(UK) Prof. Popat is a consultant thoracic medical oncologist at The Royal Marsden Hospital and professor of thoracic oncology at The Institute of Cancer Research, London, United Kingdom. He is internationally recognised as an expert in the treatment of lung cancer, mesothelioma, and thymic malignancies.
Prof. Popat qualified in 1994 from Guy’s and St Thomas’ Hospitals, London, with a triple distinction and obtained his PhD in molecular genetics in 2002, after which he undertook a postdoctoral clinician scientist fellowship and a Higher Education Funding Council for England clinical senior lectureship. He has been awarded national and international prizes for his research, in addition to four research fellowships. His interests include lung cancer and other thoracic malignancies, with a focus on the complexities of genetic profiling in cancer, including the optimisation and implementation of genomics into routine clinical practice, as well as development of novel drug treatments through clinical trials.
Prof. Popat also holds several national and international roles. Nationally, he chairs the British Thoracic Oncology Group Research Group. Internationally, he sits on the Foundation Council of the European Thoracic Oncology Platform and serves on the Thoracic Faculty for the European Society of Medical Oncology. His research on ctDNA testing and novel drugs has led to implementation in international treatment guidelines and National Health Service funding approvals.
Prof. Popat qualified in 1994 from Guy’s and St Thomas’ Hospitals, London, with a triple distinction and obtained his PhD in molecular genetics in 2002, after which he undertook a postdoctoral clinician scientist fellowship and a Higher Education Funding Council for England clinical senior lectureship. He has been awarded national and international prizes for his research, in addition to four research fellowships. His interests include lung cancer and other thoracic malignancies, with a focus on the complexities of genetic profiling in cancer, including the optimisation and implementation of genomics into routine clinical practice, as well as development of novel drug treatments through clinical trials.
Prof. Popat also holds several national and international roles. Nationally, he chairs the British Thoracic Oncology Group Research Group. Internationally, he sits on the Foundation Council of the European Thoracic Oncology Platform and serves on the Thoracic Faculty for the European Society of Medical Oncology. His research on ctDNA testing and novel drugs has led to implementation in international treatment guidelines and National Health Service funding approvals.
Tuesday, 16 June 2026
12:00–13:00 CEST
Speakers: Prof. Tony Mok and Prof. Geoffrey Liu
Duration
Session title
Speaker
3 min
Welcome and introduction
Prof. Tony Mok
25 min
Redefining outcomes with the lorlatinib 7-year CROWN data
Prof. Tony Mok
15 min
Achieving durable response by prioritising patients and their care partners
Case study presentation
Case study presentation
Prof. Geoffrey Liu
15 min
What do these latest data mean for patients?
Panel discussion and live Q&A
Panel discussion and live Q&A
Prof. Tony Mok
Prof. Geoffrey Liu
Prof. Geoffrey Liu
2 min
Summary and close
Prof. Tony Mok
Wednesday, 17 June 2026
18:00–19:00 CEST
Speakers: Dr Justin Gainor and Prof. Sanjay Popat
Duration
Session title
Speaker
3 min
Welcome and introduction
Dr Justin Gainor
25 min
Redefining outcomes with the lorlatinib 7-year CROWN data
Dr Justin Gainor
15 min
Achieving durable response by prioritising patients and their care partners
Case study presentation
Case study presentation
Prof. Sanjay Popat
15 min
What do these latest data mean for patients?
Panel discussion and live Q&A
Panel discussion and live Q&A
Dr Justin Gainor
Prof. Sanjay Popat
Prof. Sanjay Popat
2 min
Summary and close
Dr Justin Gainor
Join us for an insightful discussion on the future of ALK + aNSCLC care.
The 7-year CROWN data represent an important milestone in ALK + aNSCLC treatment. In this interactive webinar, leading experts will explore the real-world implications of the data and what they mean for long-term, patient-centred care.
During this webinar, we will:
- Discover how the 7-year CROWN data set a new benchmark in ALK + aNSCLC, enabling a shift toward long-term disease control and chronic condition management
- Explore strategies to achieve durable response with 1L lorlatinib treatment, through real-world case studies that support proactive, patient-centred preparation and therapy management
- Share expert perspectives on the evolving ALK + aNSCLC treatment landscape and the impact of recent data on treatment decisions and what these mean for patients
We will encourage you to take an active role in shaping the discussion on the treatment of ALK + aNSCLC during the live panel discussion and Q&A session.